Abstract:Chromosomal abnormalities and genomic instability in 10q22.3 region have been associated with lung cancer development, histopathological staging, and poor prognosis. Genetic mapping identified several genes including ZMIZ1, SFTPA1 and SFTPA2 in this critical region. Loss, interruption or gain of function of these genes in association with 10q22.3 deletions, translocations, or amplifications that were frequently detected in human primary lung cancer and cancer cell lines may promote oncogenesis. Human ZMIZ1, also named hZimp10, is a novel PIAS (protein inhibitor of activated STAT)-like protein that shares a zing finger domain, MIZ (MSX-interacting zinc finger), with other PIAS proteins. Fusion of ZMIZ1 to ABL1 with a t(9;10)(q34;q22.3) translocation was identified in a B-cell acute lymphoblastic leukemia patient. In this study, we performed fluorescence in situ hybridization (FISH) using genomic DNA probes covering ZMIZ1 and SFTPA gene loci at 10q22.3 to determine chromosomal aberrations involving the ZMIZ1 gene in primary lung tumor samples and lung cancer cell lines. Chromosomal abnormalities at 10q22.3 loci, including deletions, polysomy, and translocations were frequently detected in tumors and tumor-derived cell lines. We analyzed copy number variations specifically linked to ZMIZ1 gene loci by mining the published genome-wide SNP dataset from 370 NSCLC tumor samples and confirmed a significant copy number gain with average copy numbers (CN) > 5 or loss with CN < 1.5, respectively. A high frequency of loss of heterozygosity (LOH) of ZMIZ1 and ABL1 genes in lung cancer cell lines and high level amplifications of ZMIZI gene (CN > 7) in breast and prostate cancer cell lines were also detected in Sanger SNP and CGP databases, respectively. We performed Spectral karyotyping (SKY) analysis to identify chromosomal abnormalities and potential translocations involved in the 10q region in lung cancer cell lines. We found that the 10q region was translocated and fused with other chromosomes extensively in H1819 cells. This result was consistent with the high frequency 10q chromosomal abnormalities detected in human lung and other cancer cell lines in the NCI/NCBI SKY/M-FISH & CGH database. Furthermore, we developed and performed a high-throughput RACE-PCR-based gene-specific RNA sequencing analysis using next-generation parallel sequencing technology (454 Life Sciences, Inc.) to search for potential transcriptional variants and fusion partners of the ZMIZ1 gene in lung cancer cell lines which has revealed potential fusion mRNA. These results suggest that ZMIZ1 may play an important role in lung cancer development and serve as a useful biomarker for lung cancer molecular staging and prognosis. (Supported by NIH/NCI grants SPORE P50CA70907 and RO1CA116322) Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1177.

Applications of novel monoclonal antibodies specific for Ciz 1 in evaluating its levels in cancer tissues and plasma from lung cancer patients

Integrated Bioinformatics Analysis and Clinical Validation Reveals That High Expression of Mucin 1 in Intrahepatic Cholangiocarcinoma Predicts Recurrence after Curative Resection.

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

Loss of LIMCH1 Predicts Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics

Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker

Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches

Nuclear Matrix Protein Ciz1 and Cancer

Comprehensive analysis of the potential biological significance of CCL5 in pan-cancer prognosis and immunotherapy

Development of a monoclonal antibody to ITPRIPL1 for immunohistochemical diagnosis of non-small cell lung cancers: accuracy and correlation with CD8+ T cell infiltration

Systematic pan-cancer analysis insights into ICAM1 as an immunological and prognostic biomarker

Up-regulation of 14-3-3Z in Lung Cancer and Its Implication as Prognostic and Therapeutic Target

KIAA0101 as a new diagnostic and prognostic marker, and its correlation with gene regulatory networks and immune infiltrates in lung adenocarcinoma

Zinc finger C3H1-type containing serves as a novel prognostic biomarker in human pan-cancer

Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and Its Role in Evaluation of Prognosis

ZBP1 as a prognostic biomarker correlated with cell proliferation in clear cell renal cell carcinoma

A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

Dendritic Cell-Related Immune Marker CD1C for Predicting Prognosis and Immunotherapy Opportunities of Lung Adenocarcinoma Patients

Collagen type 1 alpha 1 chain is a novel predictive biomarker of poor progression-free survival and chemoresistance in metastatic lung cancer

Abstract 1177: Genomic Abnormality and Genetic Alterations of a Novel ZMIZ1 Gene at Human Chromosome 10q22.3 in Oncogenesis and Prognosis

Identification of CLIC5 as a Prognostic Biomarker and Correlated Immunomodulator for Lung Adenocarcinoma

MARCH1 as a novel immune-related prognostic biomarker that shapes an inflamed tumor microenvironment in lung adenocarcinoma